Acrivon Therapeutics(US:ACRV)2025-11-13 21:10Financial Performance - Acrivon Therapeutics reported a net loss of $18.2 million for Q3 2025, an improvement from a net loss of $22.4 million in Q3 2024, representing a 18.8% reduction in losses[6] - Total operating expenses for Q3 2025 were $19.7 million, down from $25.1 million in Q3 2024, indicating a 21.5% decrease[16] Research and Development - Research and development expenses decreased to $13.6 million in Q3 2025 from $18.9 million in Q3 2024, reflecting a 28% reduction due to fewer scheduled milestones and a focus on endometrial cancer[9] - The ongoing Phase 2b trial of ACR-368 for endometrial cancer is designed to evaluate its efficacy in patients who have received prior treatments, with enrollment and dosing ongoing[7] - Initial clinical activity for ACR-2316 has been observed, with tumor shrinkage and confirmed partial responses across several solid tumor types during the Phase 1 trial[7] - Acrivon plans to report initial clinical data from the Phase 1 study of ACR-2316 in the second half of 2025[8] - The company is advancing a new potential first-in-class cell cycle drug discovery program towards candidate nomination in 2025[8] Regulatory and Clinical Designations - ACR-368 has received Fast Track designation from the FDA for its potential as a monotherapy in endometrial cancer patients[12] Financial Position - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $134.4 million, expected to fund operations into Q2 2027[10] Data Presentation and Innovation - The company presented data at the AACR-NCI-EORTC conference demonstrating the predictive capabilities of its AP3 platform in drug design and pathway activity assessment[5]